Log in to search using one of your social media accounts:

 

AI method lowers radiation dose, speeds scanning times

An artificial intelligence (AI) technique developed at Massachusetts General...Read more on AuntMinnie.comRelated Reading: AI advances MRI for prostate cancer patients Is artificial intelligence ethical in healthcare? Deep learning may produce sharp reductions in DBT dose AI can help distinguish lung nodules on CT scans Can AI help in the fight against gadolinium deposition?
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news

Related Links:

In this report, we present an atypical FMF case with E148Q/L110P mutations in MEFV. The patient experienced periodic episodes of systemic pain originating from prostate cancer bone metastases. The pain attacks were prevented by continuous prophylactic therapy with colchicine. In this case, the presence of atypical FMF may have modulated the clinical manifestations of cancer bone metastases. To our knowledge, this is the first report to demonstrate the potential modulatory effect of MEFV mutations on cancer manifestations. PMID: 29780113 [PubMed - as supplied by publisher]
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
Does seeking information online about breast and prostate cancer impact patients'decision making regarding preventive screenings?Preventing Chronic Disease
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news
Sun Pharma had acquired YONSA from Churchill Pharmaceuticals and will commercialise the drug in the US.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
A new analysis of PROSPER, presented at AUA 2018, suggests enzalutamide plus ADT may be superior to ADT alone in nonmetastatic CRPC.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Tags: AUA Annual Meeting News Prostate Cancer Source Type: news
Conclusions: The primary endpoint of the study was not met. Lovastatin, as administered in this trial, did not reduce the incidence of grade 2 or higher rectal toxicity compared with historical controls.
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Genitourinary Source Type: research
The objective was to query how specialty influences treatment recommendations for high-risk prostate cancer in 3 clinical settings: upfront management, postoperative management, and management of biochemical recurrences (BCRs) after radiotherapy (RT). We hypothesized that specialty bias would manifest in all settings, trumping available evidence. Methods: A survey of practicing urologists and radiation oncologists was distributed through electronic mail. Questions pertained to upfront management, postoperative treatment, and local salvage for postradiation BCRs. The associations between 26 selected categorical responses...
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Genitourinary Source Type: research
We report patient-reported outcomes (PROs) from a randomized trial comparing hypofractionated and conventional prostate radiotherapy. Methods: Men with localized prostate cancer were enrolled in a trial that randomized men to either conventionally fractionated intensity-modulated radiation therapy (CIMRT, 75.6 Gy in 1.8 Gy fractions) or to dose-escalated hypofractionated IMRT (HIMRT, 72 Gy in 2.4 Gy fractions). Questionnaires assessing urinary, bowel, and sexual function were completed pretreatment and at 2, 3, 4, and 5 years after treatment. Results: Of 203 eligible patients, 185 were evaluable for PROs. A total of ...
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Genitourinary Source Type: research
Sharpest decrease seen in privately insured men after 2011
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Family Medicine, Geriatrics, Internal Medicine, Oncology, Pathology, Urology, Journal, Source Type: news
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Family Medicine, Oncology, Reproductive Medicine, Preventive Medicine, News, Source Type: news
Condition:   Prostate Cancer Interventions:   Drug: Fermented Soy;   Other: Placebo Sponsor:   Yale University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | CT Scan | Learning | Lung Transplant | Medical Ethics | PET Scan | Prostate Cancer | Radiology | Universities & Medical Training